Cardiovascular Systems, Inc. (CSII) Stock Analysis

Cardiovascular Systems, Inc. (CSII) Healthcare & Pipeline Overview

Cardiovascular Systems, Inc. (CSII) specializes in medical devices for treating peripheral and coronary artery diseases, offering catheter-based platforms and the Diamondback 360 OAS. With a focus on addressing calcified lesions, CSII operates in the competitive medical device market, serving both domestic and international healthcare providers.

What Is the Investment Thesis for CSII?

Cardiovascular Systems, Inc. presents a focused investment opportunity within the medical device sector, specifically targeting the treatment of peripheral and coronary artery diseases. The company's Diamondback 360 OAS technology offers a unique solution for treating calcified lesions, a significant challenge in stent delivery. With a market capitalization of $844M and a gross margin of 73.1%, CSII demonstrates a strong potential for profitability despite a current profit margin of -15.6%. Growth catalysts include the expansion of its product line through partnerships, such as the collaboration with Chansu Vascular Technologies, and increasing adoption of its OAS technology in both domestic and international markets. Key value drivers include the aging population and the rising prevalence of cardiovascular diseases, which are expected to drive demand for CSII's products. The company's beta of 0.74 suggests lower volatility compared to the overall market.

Based on FMP financials and quantitative analysis

CSII Key Highlights

Market capitalization of $844M indicates CSII's current valuation in the medical device market.

• Gross margin of 73.1% demonstrates strong pricing power and efficient production of its medical devices.
• Profit margin of -15.6% reflects ongoing investments in R&D and commercialization efforts, which could yield future profitability.
• Beta of 0.74 suggests lower volatility compared to the overall market, making it a potentially stable investment.
• Partnership with Chansu Vascular Technologies, LLC to develop novel drug-coated balloons, expanding its product pipeline.

Who Are CSII's Competitors?

CSII is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CSII's Key Strengths?

Innovative Diamondback 360 OAS technology.

• Strong gross margin of 73.1%.
• Established presence in the U.S. market.
• Strategic partnerships for product development.

What Are CSII's Weaknesses?

Current negative profit margin (-15.6%).

• Reliance on a limited number of key products.
• Competition from larger medical device companies.
• Exposure to regulatory risks and compliance requirements.

What Could Drive CSII Stock Higher?

Increasing adoption of Diamondback 360 OAS technology in hospitals and outpatient centers.

• Potential regulatory approvals for new product lines and indications.
• Expansion of strategic partnerships to develop and commercialize innovative cardiovascular solutions.
• Growing prevalence of cardiovascular diseases driving demand for CSII's products.

What Are the Key Risks for CSII?

Negative return on equity (-14.2%) — the business is not currently generating profit on shareholder capital.

• Intense competition from larger medical device companies with greater resources.
• Changes in healthcare regulations and reimbursement policies impacting product adoption.
• Product liability claims and recalls.
• Dependence on key personnel and the ability to attract and retain talent.
• Disruptions in the supply chain affecting the availability of critical components.

What Are the Growth Opportunities for CSII?

• Expansion of Diamondback 360 OAS technology: The Diamondback 360 OAS technology represents a significant growth opportunity for CSII. As the prevalence of calcified coronary and peripheral artery lesions increases, the demand for effective atherectomy solutions will also rise. CSII can leverage its existing technology to expand its market share by targeting new geographies and applications within the cardiovascular space. This expansion could potentially tap into a market estimated to be worth billions of dollars, with ongoing growth driven by the aging population and advancements in interventional cardiology.
• Strategic partnerships and collaborations: CSII's partnership with Chansu Vascular Technologies, LLC to develop novel drug-coated balloons represents a strategic growth opportunity. By collaborating with other companies, CSII can expand its product portfolio and access new technologies and markets. These partnerships can accelerate product development, reduce costs, and enhance CSII's competitive position in the cardiovascular device market. The drug-coated balloon market is projected to grow significantly, offering substantial revenue potential for CSII.
• Geographic expansion into international markets: CSII has the opportunity to expand its presence in international markets. By targeting countries with growing healthcare infrastructure and increasing prevalence of cardiovascular diseases, CSII can tap into new revenue streams and diversify its geographic footprint. This expansion requires navigating regulatory hurdles and establishing distribution networks, but the potential rewards are significant. Emerging markets in Asia and Latin America present particularly attractive opportunities for CSII's products.
• Development of next-generation atherectomy devices: Investing in research and development to create next-generation atherectomy devices is crucial for CSII's long-term growth. By continuously innovating and improving its technology, CSII can maintain its competitive edge and capture new market segments. This includes developing devices that are more effective, easier to use, and compatible with a wider range of patient anatomies. The market for advanced atherectomy devices is expected to grow as physicians seek more sophisticated solutions for treating complex cardiovascular lesions.
• Increased adoption in outpatient settings: There is a growing trend toward performing cardiovascular procedures in outpatient settings, such as ambulatory surgery centers (ASCs). CSII can capitalize on this trend by promoting the use of its products in these settings. Outpatient procedures offer several advantages, including lower costs and greater patient convenience. By partnering with ASCs and providing training and support, CSII can drive increased adoption of its products and expand its market reach. The shift towards outpatient care is expected to continue, creating a significant growth opportunity for CSII.

What Are CSII's Competitive Advantages?

• Proprietary Diamondback 360 OAS technology provides a competitive advantage in treating calcified lesions.
• Established relationships with hospitals and healthcare providers.
• Strong intellectual property portfolio protecting its key technologies.
• Partnerships with other companies to expand its product offerings and market reach.

What Does CSII Do?

Cardiovascular Systems, Inc. (CSII), founded in 1989 and headquartered in Saint Paul, Minnesota, is a medical technology company focused on developing and commercializing innovative solutions for treating peripheral and coronary artery diseases. Originally named Shturman Cardiology Systems, Inc., the company rebranded in January 2003 to reflect its broader cardiovascular focus. CSII's core offerings include a range of products designed to treat various plaque types in both above and below the knee arteries, addressing limitations associated with traditional surgical, catheter, and pharmacological treatments. These peripheral artery disease (PAD) products consist of catheter-based platforms and peripheral support products. A key product is the Diamondback 360 Coronary orbital atherectomy system (OAS), designed to facilitate stent delivery in patients with coronary artery disease (CAD) who are candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. CSII also offers guidewires, catheters, balloons, and embolic protection systems to support its OAS technology. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons, expanding its product pipeline and therapeutic capabilities. CSII operates both in the United States and internationally, serving hospitals and healthcare providers with its specialized cardiovascular solutions.

What Products and Services Does CSII Offer?

• Develops and commercializes solutions for treating peripheral artery disease (PAD).
• Offers catheter-based platforms for treating various plaque types in arteries above and below the knee.
• Provides solutions for calcified plaque, addressing limitations of surgical, catheter, and pharmacological treatments.
• Offers the Diamondback 360 Coronary orbital atherectomy system (OAS) for coronary artery disease (CAD).
• Facilitates stent delivery in patients with severely calcified coronary artery lesions.
• Provides guidewires, catheters, balloons, and embolic protection systems.
• Partners with Chansu Vascular Technologies, LLC to develop novel drug-coated balloons.

How Does CSII Make Money?

• Develops and manufactures medical devices for treating cardiovascular diseases.
• Sells its products directly to hospitals and healthcare providers.
• Generates revenue from the sale of its Diamondback 360 OAS and related support products.
• Expands its product line through strategic partnerships and collaborations.

What Industry Does CSII Operate In?

Cardiovascular Systems, Inc. operates in the medical device industry, which is characterized by continuous innovation and increasing demand for minimally invasive procedures. The market for cardiovascular devices is driven by the rising prevalence of heart diseases and an aging global population. Competition includes established players and innovative startups. CSII differentiates itself with its Diamondback 360 OAS technology, targeting calcified lesions in coronary and peripheral arteries. The industry is subject to stringent regulatory requirements, influencing product development and market access.

Who Are CSII's Key Customers?

• Hospitals and medical centers in the United States.
• International healthcare providers and distributors.
• Interventional cardiologists and vascular surgeons.
• Ambulatory surgery centers (ASCs).

Company Profile

Cardiovascular Systems, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Saint Paul, US. The company is led by CEO Scott Raymond Ward MS. CSII has traded publicly since 2006.

Cardiovascular Systems, Inc.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 6.12 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Cardiovascular Systems, Inc. stands at -14.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -11.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.05 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.7%, the inverse of the P/E and a quick read on earnings relative to price.

CSII Valuation & Market Position

With a $844M market cap, Cardiovascular Systems, Inc. sits in the small-cap segment of the market.

CSII Financials

CSII Latest News

No recent news available for CSII.

Common Questions About CSII (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources